Objective To assess the effect of reproductive factors, especially hormone replacement therapy (HRT) and its interaction with HLA-DRB1 *01 and/or *04 alleles on the diagnosis of rheumatoid arthritis (RA) and the presence of anti-cyclic citrullinated peptide (CCP) antibodies in women included in the ESPOIR cohort (early arthritis cohort). Methods 568 patients were included in the analyses, which were performed using logistic regression.
INTRODUCTION
Rheumatoid arthritis (RA) is a complex multifactorial disease involving both genetic and environmental factors. Some alleles of HLA-DRB1 called the shared epitope (SE) (ie, *0101, 0104, 0404, 0102, 0408 alleles) are associated with the development of a subset of RA with rheumatoid factor (RF) or anticyclic citrullinated peptide (anti-CCP) antibodies. [1] [2] [3] The involvement of female hormones in the pathogenesis of RA has been suggested by numerous observations, and many studies have evaluated hormonal treatments and other reproductive factors with confl icting results. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] The ESPOIR cohort (French acronym for Study and Follow-up of Undifferentiated Early Arthritis) is a large national multicentre cohort of 813 adults with early arthritis. 15 16 Data regarding demographic and socioeconomic factors, comorbidities, reproductive factors in women, autoimmunity and HLA-DRB1 (*01 and *04 alleles) were collected at baseline (more details are given in the online supplement).
Hormonal replacement therapy may reduce the risk for RA in women with early arthritis who carry HLA-DRB1 *01 and/or *04 alleles by protecting against the production of anti-CCP: results from the ESPOIR cohort Carine Salliot, 1,2 Claire Bombardier, 2,3 Alain Saraux, 4 Bernard Combe, 5 Maxime Dougados 1 ▶ Additional data are published online only. To view these fi les please visit the journal online (http://ard.bmj.com).
The objective of this study was to assess the effect of reproductive factors on the risk of the production of anti-CCP antibodies and the development of RA in women with early arthritis, especially the infl uence of hormone replacement therapy (HRT) and its interaction with HLA-DRB1 *01 and/or *04 alleles.
METHODS

Study population
A total of 568 women with early arthritis were included in the ESPOIR cohort and the study population (see fi gure 1).
Identifi cation of the outcomes
The two outcomes were the presence of anti-CCP2 at baseline and the diagnosis of RA at 1 year of follow-up. The American College of Rheumatology (ACR) 1987 criteria for the diagnosis of RA have a limited value in the early stage of the disease but, when combined with the opinion of a rheumatologist for the diagnosis of RA, they are sensitive (87%) and highly specifi c (99% compared with 75%). 17 The Scientifi c Committee of the ESPOIR cohort therefore defi ned RA at 1 year of follow-up by the fulfi lment of the ACR 1987 criteria (either at baseline or at 6-or 12-month follow-up visit) plus the rheumatologist's global assessment for the diagnosis of RA of at least 75 on a scale of 0-100 at 12 months.
Independent variables
The following data were assessed as potential associated factors with RA and production of anti-CCP antibodies: menopausal status, age at menopause, age at menarche, use of HRT, use of oral contraceptives, number of pregnancies, delivery within 6 months of onset and poor pregnancy outcomes (spontaneous abortion, therapeutic abortion and preterm delivery). We also evaluated the relationship between HLADRB1*01 and/or *04 alleles and hormonal treatments.
Statistical analyses
Univariate analysis and binary logistic regression were performed. More details are given in the online supplement.
RESULTS
Characteristics of study population at baseline
Among the 568 women, 275 had a diagnosis of RA and 293 had no RA (275 with undifferentiated arthritis, 18 patients with another rheumatic disease) (fi gure 1). Table 1 shows the main baseline characteristics of the study patients. Two hundred and sixty-one women (45.9%) were postmenopausal and the mean±SD age at menopause was 49.4±4.8 years (range 22-61). A total of 160 patients (61.3%) had taken HRT (mean±SD duration 6.3±4.6 years), of whom 76 were still taking it at baseline. Among the patients who received HRT, 75 (46.8%) had used oral contraceptives. The mean±SD age at menarche was 13.0±1.6 years. A total of 109 women were nulliparous (19.2%); the mean±SD number of pregnancies per woman was 2.1±1.7 and 17 women (3.0%) had a delivery within 6 months of the onset of rheumatic disease. A total of 141 women (24.8%) experienced at least one pregnancy with a poor outcome: 101 had at least one spontaneous abortion, 43 a preterm delivery and 13 women had a therapeutic abortion (see table 1w in online supplement).
The results of univariate analysis for both outcomes are shown in table 1w in the online supplement. No signifi cant difference was seen in menopausal status, age at menopause, age at menarche, delivery during the 6 months before onset of rheumatic disease, the number of pregnancies and a history of poor pregnancy outcome. A history of at least one pregnancy and the use of oral contraceptives were signifi cantly more frequent in the anti-CCP negative group (see table 1w in online supplement). Nevertheless, after adjustment for several confounding factors including age, ethnicity, marital status, work status, obesity, hypertension and smoking, we could not confi rm these associations.
Infl uence of HLADRB1 *01 and/or *04 alleles, HRT and a combination of the two on the diagnosis of RA at 1 year Logistic regression suggested that HRT may reduce the risk of RA due to the SE (table 2) . Indeed, in women with HLADRB1 *01 and/or *04 alleles, taking HRT reduced the OR from 1.88 (95% CI 1.32 to 2.68, p<0.000) for HLADRB1 *01 and/or *04 alleles alone to 1.07 (95% CI 0.51 to 2.26, p=0.85). Nevertheless, HRT alone was not signifi cantly associated with RA (OR 0.61, 95% CI 0.36 to 1.04, p=0.07). In patients with HLADRB1 *01 and/or *04 alleles, the frequency of RA was signifi cantly lower if they had ever received HRT than if they had not (8.1% vs 22%, p=0.002 for interaction, likelihood ratio test). This result suggested an interaction between HLADRB1 *01 and/or *04 alleles and HRT for the development of RA.
Infl uence of HLADRB1 (*01 and/or *04 alleles), HRT and a combination of the two on the presence of anti-CCP antibodies at baseline
Univariate analysis showed that patients without anti-CCP antibodies were more likely to have ever taken HRT (33% vs 20.4%, p=0.001) (see table 1w in online supplement). After adjustment for confounding factors (shown in the footnote to table 2), HRT may protect against the production of anti-CCP antibodies (OR 0.43, 95% CI 0.24 to 0.77, p=0.005). With regard to the relationship between HRT and anti-CCP+, the duration of HRT may also have a role; the OR for patients who had taken HRT for 6-9 years was 0.42 (95% CI 0.14 to 0.84, p=0.028) compared with 0.35 (95% CI 0.16 to 0.75, p=0.007) when HRT has been taken for at least 10 years while, in those who had taken HRT for <6 years, the results were not signifi cant (using patients who never received HRT as reference and after adjustment for the confounding factors listed in table 2). Moreover, HRT Among the patients with HLADRB1 *01 and/or *04 alleles who received HRT, 6.4% had anti-CCP antibodies compared with 21.5% of women who had never taken HRT (p<0.0001 for interaction, using the likelihood ratio test). These results also suggest an interaction between HLADRB1 *01 and/or *04 alleles and HRT on the risk for the presence of anti-CCP antibodies.
DISCUSSION
The SE (defi ned as the presence of HLADRB1 *01 and/or *04 alleles in some studies) is a well-known risk factor for RA, especially seropositive RA. 18 There is also evidence of an interaction between smoking and these HLADRB1 alleles as a risk factor for the presence of anti-CCP antibodies and a diagnosis of RA. [1] [2] [3] A major fi nding of this study is the suggestion of a new geneenvironment interaction. It is hypothesised that HRT interacts with HLADRB1 (*01 and/or *04 alleles) and reduces the risk of developing RA, probably by reducing the risk for the presence of anti-CCP antibodies. Some previous studies did not fi nd any association between HRT and the development of RA 10-14 but, to our knowledge, none assessed the interaction between HRT and some HLADRB1 alleles.
The analyses were performed using a large sample of patients included in a nationwide cohort of women with early arthritis (n=568) with no missing data regarding outcomes, independent variables and covariates (except 23 missing data on HLADRB1 genotyping) which has the required power for the analyses (>80%). We used binary logistic regression to assess, after adjustment, the infl uence of HRT and its interaction with HLADRB1 *01 and/or *04 alleles on the diagnosis of RA and the presence of anti-CCP antibodies. Before and after adjustment for several confounding factors, the results expressed in ORs were stable, which provided strength to the fi ndings.
Because tobacco smoking is a potential risk factor for RA and anti-CCP antibodies, the apparent protective effect of HRT on the presence of anti-CCP antibodies could be explained by fewer smokers among women who received HRT. Among the 160 women who used HRT, 62.5% never smoked and 37.5% ever smoked, but this difference was not signifi cant (p=0.21). Moreover, in the logistic regression we included the cumulative dose of tobacco (from 0 for non-smokers to 60 pack-years) as a confounding factor (see table 2, model 2).
No excess risk for RA is observed during pregnancy, perhaps because of the immunosuppressive effects of oestrogen and progesterone (regulation of production or action of cytokines such as tumour necrosis factor α and interleukins 1, 6, 12 and 10). The increased risk of RA in postpartum breast feeding women might be explained by the high concentration of prolactin and the fall in oestrogen and progesterone levels after delivery. 19 20 Brennan et al 19 suggested that the polymorphisms of the prolactin gene would be in linkage disequilibrium with HLADR4, prolactin gene and the HLA region being located close on the short arm of chromosome 6. Postmenopausal women who carry HLADR4 may therefore have an increased risk for RA (mediated by an increased prolactin level and low concentrations of oestrogen and progesterone). In these women, taking HRT may reduce this risk through the immunosuppressive effect of oestrogen and progesterone.
These results indicate another potential gene-environment interaction associated with RA and anti-CCP antibodies. Further studies are needed to confi rm these fi ndings and to better understand the interaction between HLADR1 or DR4 and female hormones. 
